Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Open-Label Extension Study to Investigate the Safety of SER120 Nasal Spray Formulations in Patients With Nocturia Completing Study SPC-SER120-DB1-200901 or Study SPC-SER120-DB2-200902

NCT00981682 is registered in ClinicalTrials.gov with Serenity Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00981682
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00981682 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Open-Label Extension Study to Investigate the Safety of SER120 Nasal Spray Formulations in Patients With Nocturia Completing Study SPC-SER120-DB1-200901 or Study SPC-SER120-DB2-200902
Lead sponsor
Serenity Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
August 31, 2009
Completion date
August 31, 2011
Enrollment
376 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nocturia